Clinical management of neoplastic and non-neoplastic lung diseases has changed significantly in the past decade. Therefore, there is much greater pressure on the practicing pathologist not only to make the correct diagnosis, but also to guide therapeutic decisions and management of patients with lung diseases. This course will provide a detailed discussion on potentially difficult aspects of recent recommendations for the classification of chronic interstitial pneumonias, challenging areas of the upcoming WHO classification of lung and mesothelial tumors, and recently recognized biomarkers of response to immune check point inhibitors. An update on acute lung injury in the context of the recent E-cigarette/vaping outbreak and COVID pandemic will be provided. Upon completion of the course participants should be able to integrate histology, radiology, emerging molecular techniques and clinical information in the diagnosis of thoracic entities.
LEARNING OBJECTIVES
- Update current knowledge on recent advances and practice guidelines in neoplastic and non-neoplastic diagnostic thoracic pathology
- Recognize key morphological features, mimickers, and ancillary studies that can help in making a specific and accurate diagnosis in thoracic pathology
- Integrate histology, ancillary techniques and clinical information in the diagnosis and management of difficult diagnostic areas of thoracic neoplastic and non-neoplastic pathology
TARGET AUDIENCE
- Practicing academic pathologists
- Practicing community pathologists
- Pathologists-in-Training
| FACULTY | TITLE |
|---|---|
| Sanja Dacic, MD, PhD University of Pittsburgh |
Introduction |
| Mary Beth Beasley, MD Mount Sinai Medical Center, New York |
Acute lung injury: From Cannabis to COVID |
| In order of preferred presentation for on-demand viewing | |
| FACULTY | TITLE |
| Maxwell L. Smith, MD Mayo Clinic Arizona |
Diagnosis of IPF/UIP- where we are and where we need to go |
| Andrew Churg, MD, PhD The University of British Columbia |
Chronic hypersensitivity pneumonitis practice recommendations and challenges |
| Alain Borczuk, MD Weill Cornell Medicine |
Different faces of invasion in lung carcinoma |
| Natasha Rekhtman, MD, PhD Memorial Sloan Kettering Cancer Center Department of Pathology |
Neuroendocrine tumors of the lung- a decade of change |
| Sanja Dacic, MD, PhD University of Pittsburgh |
Pleural mesothelioma classification –update and challenges |
| Jennifer M. Boland Froemming, MD Mayo Clinic |
Unusual lung tumors –from morphology to genetics |
| Lynette M. Sholl, MD Brigham and Women’s Hospital, Harvard Medical School |
Biomarkers of response to check point inhibitors– beyond PD-L1 |
Release Date :Â Saturday, March 13, 2021
